Clinical PET/MR

Recent Results Cancer Res. 2020;216:747-764. doi: 10.1007/978-3-030-42618-7_22.


Oncologic imaging has been a major focus of clinical research on PET/MR over the last 10 years. Studies so far have shown that PET/MR with 18F-Fluorodeoxyglucose (FDG) overall provides a similar accuracy for tumor staging as FDG PET/CT. The effective radiation dose of whole-body FDG PET/MR is more than 50% lower than for FDG PET/CT, making PET/MR particularly attractive for imaging of children. However, the longer acquisition times and higher costs have so far limited broader clinical use of PET/MR technology for whole-body staging. With the currently available technology, PET/MR appears more promising for locoregional staging of diseases for which MR is the anatomical imaging modality of choice. These include brain tumors, head and neck cancers, gynecologic malignancies, and prostate cancer. For instance, PET imaging with ligands of prostate-specific membrane antigen, combined with multi-parametric MR, appears promising for detection of prostate cancer and differentiation from benign prostate pathologies as well as for detection of local recurrences. The combination of functional parameters from MR, such as apparent diffusion coefficients, and molecular parameters from PET, such as receptor densities or metabolic rates, is feasible in clinical studies, but clinical applications for this multimodal and multi-parametric imaging approach still need to be defined.

Keywords: FDG; Fluorodeoxyglucose; MR/PET; Multimodal imaging; PET/MR; PET/MRI; PSMA; Prostate-specific membrane antigen.

Publication types

  • Review

MeSH terms

  • Fluorodeoxyglucose F18
  • Humans
  • Magnetic Resonance Imaging*
  • Multimodal Imaging*
  • Neoplasm Staging
  • Neoplasms / diagnostic imaging*
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography*


  • Fluorodeoxyglucose F18